PTN Stock Overview
A biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Palatin Technologies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.94 |
| 52 Week High | US$5.65 |
| 52 Week Low | US$0.68 |
| Beta | 0.94 |
| 11 Month Change | -10.62% |
| 3 Month Change | -39.06% |
| 1 Year Change | -52.84% |
| 33 Year Change | -92.70% |
| 5 Year Change | -95.30% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| PTN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.3% | -6.5% | -1.0% |
| 1Y | -52.8% | 14.6% | 30.3% |
Return vs Industry: PTN underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: PTN underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| PTN volatility | |
|---|---|
| PTN Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PTN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PTN's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 30 | Carl Spana | palatin.com |
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases.
Palatin Technologies, Inc. Fundamentals Summary
| PTN fundamental statistics | |
|---|---|
| Market cap | US$17.87m |
| Earnings (TTM) | -US$32.35m |
| Revenue (TTM) | US$2.38m |
7.7x
P/S Ratio-0.6x
P/E RatioIs PTN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PTN income statement (TTM) | |
|---|---|
| Revenue | US$2.38m |
| Cost of Revenue | US$22.50m |
| Gross Profit | -US$20.11m |
| Other Expenses | US$12.24m |
| Earnings | -US$32.35m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.66 |
| Gross Margin | -843.66% |
| Net Profit Margin | -1,357.06% |
| Debt/Equity Ratio | 0% |
How did PTN perform over the long term?
See historical performance and comparison